191 related articles for article (PubMed ID: 7715908)
1. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.
Barni S; Lissoni P; Cazzaniga M; Ardizzoia A; Meregalli S; Fossati V; Fumagalli L; Brivio F; Tancini G
Oncology; 1995; 52(3):243-5. PubMed ID: 7715908
[TBL] [Abstract][Full Text] [Related]
2. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
Lissoni P; Barni S; Fossati V; Ardizzoia A; Cazzaniga M; Tancini G; Frigerio F
Support Care Cancer; 1995 May; 3(3):194-7. PubMed ID: 7655780
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Lissoni P; Bolis S; Brivio F; Fumagalli L
Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
[TBL] [Abstract][Full Text] [Related]
4. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
[TBL] [Abstract][Full Text] [Related]
5. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
Lissoni P; Barni S; Tancini G; Ardizzoia A; Ricci G; Aldeghi R; Brivio F; Tisi E; Rovelli F; Rescaldani R
Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy.
Lissoni P; Brivio F; Fumagalli L; Di Fede G; Brera G
In Vivo; 2005; 19(6):1077-80. PubMed ID: 16277025
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
8. A study of the pineal hormone melatonin as a second line therapy in metastatic colorectal cancer resistant to fluorouracil plus folates.
Barni S; Lissoni P; Paolorossi F; Crispino S; Archili C; Tancini G
Tumori; 1990 Feb; 76(1):58-60. PubMed ID: 2321275
[TBL] [Abstract][Full Text] [Related]
9. Preoperative interleukin-2 subcutaneous immunotherapy may prolong the survival time in advanced colorectal cancer patients.
Brivio F; Lissoni P; Alderi G; Barni S; Lavorato F; Fumagalli L
Oncology; 1996; 53(4):263-8. PubMed ID: 8692528
[TBL] [Abstract][Full Text] [Related]
10. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
Lissoni P; Brivio F; Fumagalli L; Messina G; Vigoré L; Parolini D; Colciago M; Rovelli F
Anticancer Res; 2008; 28(2B):1377-81. PubMed ID: 18505083
[TBL] [Abstract][Full Text] [Related]
11. Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms.
Lissoni P
Pathol Biol (Paris); 2007; 55(3-4):201-4. PubMed ID: 17446010
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer.
Lissoni P; Meregalli S; Fossati V; Paolorossi F; Barni S; Tancini G; Frigerio F
Tumori; 1994 Dec; 80(6):464-7. PubMed ID: 7900237
[TBL] [Abstract][Full Text] [Related]
13. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
Lissoni P; Barni S; Tancini G; Mainini E; Piglia F; Maestroni GJ; Lewinski A
Oncology; 1995; 52(2):163-6. PubMed ID: 7854778
[TBL] [Abstract][Full Text] [Related]
14. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
Lissoni P; Mandalà M; Brivio F
Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status.
Lissoni P; Brivio F; Ardizzoia A; Tancini G; Barni S
Tumori; 1993 Dec; 79(6):401-4. PubMed ID: 8171739
[TBL] [Abstract][Full Text] [Related]
17. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma.
Barni S; Lissoni P; Cazzaniga M; Ardizzoia A; Paolorossi F; Brivio F; Perego M; Tancini G; Conti A; Maestroni G
Tumori; 1992 Dec; 78(6):383-7. PubMed ID: 1297233
[TBL] [Abstract][Full Text] [Related]
18. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
[TBL] [Abstract][Full Text] [Related]
19. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ
J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy with low-dose subcutaneous interleukin-2 plus beta-interferon as a second-line therapy for metastatic colorectal carcinoma.
Barni S; Lissoni P; Ardizzola A; Vigoré L; Vezzo R; Rescaldani R; Tancini G
Tumori; 1993 Oct; 79(5):343-6. PubMed ID: 8116079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
